Carboplatin, sold under the brand name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer.

[3] Common side effects include low blood cell levels, nausea, and electrolyte problems.

[3] Carboplatin is in the platinum-based antineoplastic family of medications and works by interfering with duplication of DNA.

This causes the blood cell and platelet output of bone marrow in the body to decrease quite dramatically, sometimes as low as 10% of its usual production levels.

The most notable complication of neutropenia is increased probability of infection by opportunistic organisms, which necessitates hospital readmission and treatment with antibiotics.

CBDCA and chloride are the leaving groups in these respective drugs Carboplatin exhibits slower aquation (replacement of CBDCA by water) and thus slower DNA binding kinetics, although it forms the same reaction products in vitro at equivalent doses with cisplatin.

Some results show that cisplatin and carboplatin cause different morphological changes in MCF-7 cell lines while exerting their cytotoxic behaviour.

Like cisplatin, carboplatin binds to and cross-links DNA, interfering with the replication and suppressing growth of the cancer cell.

However, toxicity from treatment was variable, and therefore Professor Hillary Calvert (University of Newcastle) developed a formula to dose carboplatin based on renal function.

[14] It's applicability at very high doses of carboplatin has been challenged[16] and in the US the Food and Drug Administration has recommended capping GFR at 125ml/min.

[6][20] It gained U.S. Food and Drug Administration (FDA) approval for carboplatin, under the brand name Paraplatin, in March 1989.

[22] Carboplatin combined with hexadecyl chain and polyethylene glycol appears to have increased liposolubility and PEGylation.